---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-097145"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:00:32.801186+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Unicycive Q3 net loss $4.1M; OLC NDA accepted with PDUFA June 2025

## Summary
- Net loss $4.1M vs $4.4M YoY; cash $32.3M expected to fund into 2026.
- FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.
- OLC patient survey: 79% preferred OLC over prior therapy; 98% said easy to take.
- UNI-494 Phase 1 completed; plans to request FDA meeting by end of 2024.
- Added to Russell Microcap Index effective July 1, 2024.

## SEC filing metadata
- accession: 0001213900-24-097145
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390024097145/0001213900-24-097145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390024097145/ea0220889-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-097145
- JSON: https://secwatch.observer/filing/0001213900-24-097145.json
- Plain text: https://secwatch.observer/filing/0001213900-24-097145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.